Ceptur: A new mechanism in RNA knockdown

The number of new companies developing RNA therapies continues to grow with the launch of Ceptur, an RNA oligonucleotide play with an alternative platform for knocking down — and editing — target RNA sequences that are difficult to address with other RNA silencing strategies. 

Ceptur Therapeutics Inc. launched with a $75 million series A round on Wednesday and a license to an RNA silencing technology that’s been in development for more than a decade. venBio Partners and Qiming Venture Partners USA co-led the round, which includes strategic investor Bristol Myers Squibb Co. (NYSE:BMY)...